Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
This was the stock's second consecutive day of losses.
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback